The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

The latest readout, from the COMP006 study, showed that two doses of the highest, 25 mg dose of COMP360, given in a ...

COMPASS Pathways CMPS shares are up during Tuesday’s premarket session following the company’s announcement of achieving the ...

Compass announced in January that the FDA had accepted its Investigational New Drug application for COMP360 for the treatment ...

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; ...